Please use this identifier to cite or link to this item:
https://scholarbank.nus.edu.sg/handle/10635/149891
Title: | GENERATION AND CHARACTERISATION OF NOVEL ANTI-GLYCAN MONOCLONAL ANTIBODY AGAINST HAEMATOLOGICAL MALIGNANCIES | Authors: | TEO CHONG KOK | Keywords: | antibody, ADC, AML, glycan, MM, mAb | Issue Date: | 17-Aug-2018 | Citation: | TEO CHONG KOK (2018-08-17). GENERATION AND CHARACTERISATION OF NOVEL ANTI-GLYCAN MONOCLONAL ANTIBODY AGAINST HAEMATOLOGICAL MALIGNANCIES. ScholarBank@NUS Repository. | Abstract: | SLAM01 was identified from a panel of mAbs raised against CD319, a marker highly expressed in Multiple Myeloma (MM). Despite the availability of an FDA-approved anti-CD319 (elotuzumab), the objective was to generate mAbs with different mechanisms of action that potentially would be more efficacious. SLAM01 was selected after flow cytometry screening and was found to bind preferentially to Acute Myeloid Leukemia (AML) cell lines rather than MM cell lines. No binding was observed on normal and primary cells. Further characterisation revealed that SLAM01 recognised an N-linked glycan epitope on but not limited to CD319 on the immunising antigen and AML cell lines. Functionally, SLAM01 and chimeric SLAM01 could inhibit AML cell growth as a naked mAb and an antibody-drug conjugate when tested in vitro and in vivo. Based on our data, SLAM01 has the potential to be developed into a therapeutic against AML, however further development is needed. | URI: | http://scholarbank.nus.edu.sg/handle/10635/149891 |
Appears in Collections: | Ph.D Theses (Open) |
Show full item record
Files in This Item:
File | Description | Size | Format | Access Settings | Version | |
---|---|---|---|---|---|---|
TeoCK.pdf | 8.8 MB | Adobe PDF | OPEN | None | View/Download |
Google ScholarTM
Check
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.